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REPLY
We appreciate Drs. Bangalore and Messerli’s interest in our study
(1). In their letter to the editor they argue that our statement—“for
patients engaging in vigorous activities . . . -blockade-based ther-
apy can protect against excessive and repetitive elevations in blood
pressure (BP) which may occur during such activities”—may be
inappropriate because it is based on peripheral BP measurements.
They present evidence for greater risk of cardiovascular events or
lower-risk reduction with beta-blockers versus other antihyperten-
sive agents (2–4) and they suggest that this lower risk is due to
lower central BP achieved by antihypertensive agents other than
beta-blockers, as supported by the 4.3-mm Hg lower central BP
reported in the CAFÉ trial (4). Finally, they suggest that for
hypertensive patients “we do need a medication that curtails their
(central) BP rise but not one that curtails their activity.”
We agree that beta-blockers are not as effective in reducing
stroke rates when compared to other antihypertensive agents.
However, it is important to point out that there are no data on
therapies and outcomes in hypertensive patients with an exagger-
ated BP response to exercise.
Our statement is based on observations that the exercise BP on
those treated with beta-blockers was 14–19 mm Hg lower at
different workloads and for different antihypertensive agents. Most
will agree that the relationship between central and peripheral BP
is direct, and a change in one (central or peripheral) will result in
a proportional change in the same direction on the other. There-
fore, it is reasonable to assume that a peripheral exercise BP that is
14–19 mm Hg lower than the BP of those treated with antihy-
pertensive agents other than beta-blockers is more likely to reflect
a proportionally lower than higher central BP.
We also agree that beta-blockers reduce exercise time. The peak
exercise time in our patients on beta-blocker-based therapy was
lower by 19 s compared to the other agents. However, we are
confident that most health care providers and patients will gladly
trade 19-s reduction in peak exercise time for 19-mm Hg lower
systolic BP during physical activities.
*Peter F. Kokkinos, PhD
Steven Singh, MD
Puneet Narayan, MD
*Veterans Affairs Medical Center/Cardiology
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Standard Deviation of Sequential Five-
Minute R-R Interval Means (SDANN)
Is a Prognostic Marker, but Not
Necessarily an Autonomic Marker
The recent study by Fantoni et al. (1) provides strong data that
standard deviation of sequential 5-minute R-R interval means
(SDANN, a long-term measure of heart rate variability [HRV]) is
an important clinical tool. The researchers have convincingly
shown that 1) successful cardiac resynchronization therapy (CRT)
improved SDANN and 2) that an early improvement in SDANN
predicted a favorable long-term outcome.
The investigators interpret this increase in SDANN as reflecting
changes in autonomic tone, specifically modifications of the sympa-
thetic nervous system and parasympathetic nervous system interac-
tions in the heart. Although we agree that short-term measures of
HRV such as high-frequency (0.15 to 0.4 Hz) and low-frequency
(0.04 to 0.15 Hz) variability have been shown to be modulated by the
autonomic nervous system, there are no data showing that SDANN
is a reflection of the autonomic nervous system.
In contrast, we have shown that SDANN is heavily influenced by
physical activity. In an earlier study, the largest contributions to the
SDANN came around the transitions going into and waking from
sleep (2). We have also shown in both patients with heart failure and
in healthy subjects that SDANN significantly increased by changing
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the activity level from periods of enforced rest to periods of scripted
activity (3). Finally, we could generate similar SDANN values by
dual-chamber pacing whether driven by sinus node activity or by a
mechanical activity sensor (4). Taken together, these findings
indicate the major role of activity in inducing SDANN.
Fantoni et al. found that the increases in SDANN were parallel
to improvements in functional capacity, and Adamson et al. (5)
reported that a decline in physical activity corresponded with a
decrease in SDANN prior to a clinical deterioration.
We propose that patients with successful CRT experience
hemodynamic improvements, an improvement in functional ca-
pacity, and an increase in physical activity with the resultant
modulation of heart rate, which is reflected by an increase in
SDANN. Finally, none of this diminishes the importance of
SDANN, but does suggest that its important role may not involve
the autonomic nervous system.
Satish R. Raj, MD, MSCI
Daniel E. Roach, PhD
Mary Lou Koshman, RN
*Robert S. Sheldon, MD, PhD
*Libin Cardiovascular Institute of Canada
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REPLY
We appreciate the important comments made by Sheldon et al.
who questioned our interpretation (1) that changes in the standard
deviation of the averages of intrinsic intervals in the 288 5-minute
segments of a day (SDANN) could reflect changes in autonomic
interactions on the heart. The criticism was based on the obser-
vation—provided by their own laboratory—that SDANN is “pos-
sibly and partly” affected by physical activity. We regret to have
overlooked their work (2), which showed that increased level of
physical activity is a possible source of the observed increase in
24-h SDANN; yet this does not imply at all that SDANN is not
an index of autonomic modulation of the heart.
Although our understanding of the physiological background of
long-term, in comparison with short-term, heart rate variability
(HRV) is more incomplete, there is ample evidence that the
autonomic nervous system also plays a major role in the genera-
tion of long-term HRV. Indeed, parasympathetic blockade with
atropine decreases 24-h HRV at all frequencies (3); after heart
transplantation, long-term HRV is reduced at all frequencies (4),
and long-term HRV is also depressed in the autonomic neuropa-
thy occurring in diabetic patients (5).
Though short-term time-domain HRV is substantially dependent
on respiratory arrhythmia and fast baroreflex regulation, long-term
measures have been regarded as reflecting the response of cardiac
regulation to challenges of daily life. Several factors have been invoked
to explain some limitations in the correlation between short- and
long-term HRV, including slower fluctuations due to baroreflexes,
neurohormonal rhythms and circadian patterns, differences between
day and night, and both physical and mental activity.
The role of a deranged baroreflex in affecting autonomic outflow to
the heart is firmly established. For example, a reduced left ventricular
function depresses baroreflex sensitivity and reduces SDNN (6). The
hemodynamic improvement brought about by cardiac resynchroniza-
tion therapy restores cardiac contractility, which results in an improve-
ment in baroreceptor activity and in long-term HRV. Whereas we
cannot exclude that an increase in physical activity might have
contributed to the observed improvement in long-term HRV, we
believe that the autonomic nervous system is the primary determinant
of HRV in both the short and long term.
In conclusion, we do not entirely share the view by Sheldon and
colleagues that the role of SDNN does not involve the autonomic
nervous system.
*Angelo Auricchio, MD, PhD
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